Overview

Cozaar XQ Re-examination Study (MK-0954-349)

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This survey is conducted for preparing application material for re-examination under the Pharmaceutical Affairs Law and its Enforcement Regulation; its aim is to reconfirm the clinical usefulness of COZAAR XQ through collecting the safety and efficacy information according to the Re-examination Regulation for New Drugs.
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Amlodipine
Losartan